HIV and AIDS Trial, Recruiting NCT06554223 Sponsor: Brigham and Women's Hospital Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT06554223
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who are living with HIV
  • People who are currently taking a specific HIV treatment regimen that includes a medicine called dolutegravir as their first-line treatment
  • People who have had a gap in their HIV care (more than 28 days late for an appointment) or had a detectable level of the HIV virus in their blood (50 copies/ml or above) at some point in the past year, based on either existing study records or clinic records
  • People who are able to give their full informed consent to take part
  • People who are willing to follow the study procedures, including keeping their contact details up to date

Note: A smaller group of participants will also be invited for in-depth interviews at or around the 24-month point in the study (confirm with trial site for details)

Who may not be able to join:

  • People with certain health conditions that their HIV doctor determines require regular in-person clinic visits, such as tuberculosis or epilepsy
  • People who are pregnant at the time of joining and need to receive care through the antenatal (pregnancy) clinic system
  • People who have consistently attended all their appointments (no gaps of more than 28 days) and have had a well-controlled level of HIV in their blood throughout the past year
  • People who are planning to leave Cape Town permanently within the next 24 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ingrid T Katz, MD, MHS, Brigham and Women's Hospital

Phone: 617-525-8194

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 November 2025
Est. completion
30 December 2028

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

Viral suppression (Viral load <50 c/ml)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov